Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Relapse · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Treatment discontinuation · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Adverse events · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Death or dependence, · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Early death (within 2 weeks of stroke onset) · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Quality of life · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: lower‐dose regimens vs standard‐dose regimens Other neonatal morbidity · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: IV maintenance vs standard IM maintenance regimen Severe morbidity · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: IV maintenance vs standard IM maintenance regimen Side effects · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: IV maintenance vs standard IM maintenance regimen Other neonatal morbidity · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: loading dose alone vs loading dose plus maintenance dose regimen Severe morbidity · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: duration of postpartum maintenance regimen: short vs 24 hours after delivery Death of the baby before discharge from hospital · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: duration of postpartum maintenance regimen: short vs 24 hours after delivery Maternal death · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: duration of postpartum maintenance regimen: short vs 24 hours after delivery Other neonatal morbidity · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: loading dose alone vs loading dose + maintenance regimen Severe morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: loading dose alone vs loading dose plus maintenance dose regimen Side effects · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: loading dose alone vs loading dose + maintenance regimen Side effects · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: loading dose alone vs loading dose + maintenance regimen Other neonatal morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: IV maintenance vs standard IM maintenance regimen Severe morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: IV maintenance vs standard IM maintenance regimen Side effects · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: loading dose alone vs loading dose plus maintenance dose regimen Death of the baby before discharge from hospital · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: IV maintenance vs standard IM maintenance regimen Maternal death · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: IV maintenance vs standard IM maintenance regimen Other neonatal morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: short vs standard maintenance regimen (subgroups by type of short regimen) Death of the baby before discharge from hospital · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: short vs standard maintenance regimen (subgroups by type of short regimen) Maternal death · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: short vs standard maintenance regimen (subgroups by type of short regimen) Other neonatal morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: higher vs lower IV maintenance regimen Severe morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: higher vs lower IV maintenance regimen Death of the baby before discharge from hospital · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: higher vs lower IV maintenance regimen Maternal death · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: higher vs lower IV maintenance regimen Other neonatal morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Prevention of eclampsia: maintenance regimen by continuous infusion vs a serial IV bolus regimen Severe morbidity · women with pre‐eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: loading dose alone vs loading dose plus maintenance dose regimen Other neonatal morbidity · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Treatment of eclampsia: lower‐dose regimens vs standard‐dose regimens Side effects · women with eclampsia Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Providing information about the residents? fall risk vs usual care Serious adverse events related to the use of physical restraints ‐ not measured · older people in all long‐term care settings Interventions for preventing and reducing the use of physical restraints for older people in all long‐term… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Providing information about the residents? fall risk vs usual care Duration of physical restraint use ‐ not measured · older people in all long‐term care settings Interventions for preventing and reducing the use of physical restraints for older people in all long‐term… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Providing information about the residents? fall risk vs usual care Fall‐related injuries ‐ not measured · older people in all long‐term care settings Interventions for preventing and reducing the use of physical restraints for older people in all long‐term… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Providing information about the residents? fall risk vs usual care Residents with at least one psychotropic medication ‐ not measured · older people in all long‐term care settings Interventions for preventing and reducing the use of physical restraints for older people in all long‐term… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Simple educational intervention vs usual care Serious adverse events ‐ not measured · older people in all long‐term care settings Interventions for preventing and reducing the use of physical restraints for older people in all long‐term… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Quality of life · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Adverse events · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Time to next exacerbation · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD FEV1 · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Adverse events · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) FEV1 · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |